Case Studies – Chronic Hepatitis B

Barbara Leggett
RBWH
Case 1  Mrs DC

- 33 year old lady who immigrated from mainland China 2 years ago with her husband
- Attended your practice for a check up of her hepatitis B and saw another doctor a few weeks ago
- Has come today to discuss the results of her investigations

LFTS – All normal, ALT 21
FBC – All normal, platelets 221

HepBsAg pos
HepBsAb neg
HepBcAb pos
HepBeAg neg
HepBeAb pos
HepC Ab neg

HBV DNA 763 IU/ml
Case 1 Mrs DC

What is the likely way she has acquired Hepatitis B?

a) Sexual transmission as an adult

b) From medical procedures such as vaccinations when she was a child

c) From her mother at birth

d) It is not possible to be sure
Case 1 Mrs DC

- **Family history:**
  - Mother, maternal uncles and maternal grandmother all known to have chronic hepatitis B
  - All living in China
  - None of them known to have cirrhosis or hepatocellular cancer
Case 1 Mrs DC

- What should she tell her husband?

  a) He should be vaccinated for Hepatitis B

  b) Since her viral load is low, the infection risk is minimal and nothing needs to be done

  c) He should be tested for Hepatitis BsAg and vaccinated if it is negative

  d) He should be tested Hepatitis BsAg, HepBsAb and HepBcAb and vaccinated if all are negative
Case 1 Mrs DC

- What other investigations would it be useful to order?

Liver Ultrasound: “Liver is of normal size and even echotexture. There is no focal parenchymal abnormality”
Case 1  Mrs DC

- Should she be started on antiviral treatment? Is it likely that this will be started when she is seen in a specialist clinic?
  a) Yes
  b) No

LFTS – All normal, ALT 21
FBC – All normal, platelets 221

HepBsAg pos
HepBsAb neg
HepBcAb pos
HepBeAg neg
HepBeAb pos
HepC Ab neg

HBV DNA 763 IU/ml
Case 1 Mrs DC

- At present a curative treatment does not exist
- Spontaneous conversion to sAg neg/sAb pos occurs at rate of 1% per year

- **Goal of treatment is improve survival and quality of life by preventing disease progression which would lead to cirrhosis and thus to liver failure and a high risk of hepatocellular cancer**

- **Indication to start antiviral therapy would be HBVDNA > 2000 IU/ml and elevated ALT**
- Once commenced antiviral therapy would continue indefinitely
If HBVDNA becomes >20,000 IU/ml, I will consider advising liver biopsy if she does not want to start treatment

Cirrhosis would be an absolute indication for treatment whatever the viral load or ALT but her fibroscan is normal
Case 1 Mrs DC

- Surveillance for hepatocellular cancer
  a) should be conducted with 6 monthly liver ultrasound
  b) should be conducted with 12 monthly liver ultrasound
  c) can be done with alpha fetoprotein alone
  d) is not indicated in Mrs DC’s case at present
Case 1 Mrs DC

- **HCC surveillance guidelines for patients with HepBsAg pos:**
  - 6 monthly ultrasound + AFP
- Men over 40
- Women over 50
- Cirrhosis at any age
- Family history of HCC at any age
- Africans over 21
Case 2 Mr AF

- 56 year old man found to have abnormal LFTs on check up
- Immigrated from Italy as a young man. Married with 2 daughters
- No significant PMH

LFTs: ALT 82, AST 76, otherwise normal
FBC: normal apart from platelets 93

HepBsAg pos
HepBsAb neg
HepBcAb pos
HepBeAg neg
HepBeAg pos
Hep C Ab neg
HepD Ab neg

HBVDNA 10,600 IU/ml
Case 2 Mr AF

• What is the likely way he has acquired Hepatitis B?

  a) Sexual transmission as an adult

  b) From medical procedures such as vaccinations when he was a child

  c) From his mother at birth

  d) It is not possible to be sure
Case 2 Mr AF

- What other investigations would it be useful to order?

Liver ultrasound: coarse echotexture; no space occupying lesions, normal spleen

Does this exclude cirrhosis?
Case 2 Mr AF

- He was referred to Liver Clinic and a liver biopsy was performed

- This showed chronic Hepatitis B with mild histological activity and established cirrhosis

- Nowadays a fibroscan may have given enough information to avoid the need for biopsy
Case 2 Mr AF

• How should he be treated?

a) Entecavir 0.5mg daily to be continued indefinitely

b) Tenofovir 300mg daily to be continued indefinitely

c) Continue observation planning to start treatment if viral load is rising or LFTs are worsening
Case 2 Mr AF

• Entecavir was commenced and viral load fell to <15 IU/ml and LFTs returned to normal

• Surveillance for HCC was commenced with 6 monthly ultrasound and alphafetoprotein

• First surveillance ultrasound showed a 2cm space occupying lesion. Alphafetoprotein was normal
• Primovist MRI showed characteristics of hepatocellular carcinoma
• Discussed at MDT and agreed suitable for surgery
• 2.4cm well differentiated HCC resected

• He remains well on entecavir and surveillance 10 years later
Case 3 Ms AT

- 15 year old girl attends you for a check up of her Hepatitis B
- She was born in the Phillipines and her mother was known to have Hepatitis B
- She immigrated at the age of 5 and had blood tests then
- Further blood tests are organised

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP</td>
<td>84</td>
<td>77</td>
</tr>
<tr>
<td>AST</td>
<td>21</td>
<td>65</td>
</tr>
<tr>
<td>ALT</td>
<td>18</td>
<td>110</td>
</tr>
<tr>
<td>GGT</td>
<td>6</td>
<td>20</td>
</tr>
<tr>
<td>HepBsAg</td>
<td>pos</td>
<td>pos</td>
</tr>
<tr>
<td>HepBeAg</td>
<td>pos</td>
<td>pos</td>
</tr>
<tr>
<td>HBVDNA</td>
<td>$&gt;170 \times 10^6$ IU/ml</td>
<td>$&gt;170 \times 10^6$ IU/ml</td>
</tr>
</tbody>
</table>
Case 3 Ms AT

- What is likely to be the best management?

  a) Start entecavir or tenofovir because her viral load is so high and her liver is being damaged

  b) Observe blood tests closely over the next few months in the hope she will seroconvert to HepBeAg negative and the HBVDNA will fall

  c) Start entecavir or tenofovir because there is a high risk of infecting others
## Case 3 Ms AT

<table>
<thead>
<tr>
<th>Date</th>
<th>ALT</th>
<th>HepBeAg</th>
<th>HepBeAb</th>
<th>HBVDNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov 2015</td>
<td>167</td>
<td>pos</td>
<td>neg</td>
<td>&gt;110 x 10⁶</td>
</tr>
<tr>
<td>Feb 2016</td>
<td>154</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aug 2016</td>
<td>530</td>
<td>pos</td>
<td>neg</td>
<td>&gt;110 x 10⁶</td>
</tr>
<tr>
<td>Sep 2016</td>
<td>230</td>
<td>pos</td>
<td>pos</td>
<td></td>
</tr>
<tr>
<td>Mar 2017</td>
<td>144</td>
<td>neg</td>
<td>pos</td>
<td>1.6 x 10⁶</td>
</tr>
<tr>
<td>Jun 2017</td>
<td>1010</td>
<td>neg</td>
<td>pos</td>
<td>11 x 10⁶</td>
</tr>
</tbody>
</table>

Started entecavir 0.5mg daily in June 2017 to be continued indefinitely

**August 2017:** ALT 46 HBV DNA 440 IU/ml
**°°** HBV DNA levels can be between 2,000 and 20,000 IU/ml in some patients without signs of chronic hepatitis

* Persistently or intermittently

---

*J Hepatol 2017; 67:370-398*
Hepatitis B Virus

## Emergency

- Other useful information for referring practitioners (Not an exhaustive list)

### Minimum Referral Criteria

<table>
<thead>
<tr>
<th>Category 1</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appointment</td>
<td>Patients who are HBsAg positive with Red flags or ALT &gt;100</td>
</tr>
<tr>
<td></td>
<td>Pregnant women who are HBsAg positive and have HBV DNA &gt;10^6IU/ml or abnormal ALT</td>
</tr>
</tbody>
</table>

- Presence of Red flags
  - Evidence of liver decompensation i.e. jaundice and/or ascites and/or encephalopathy

<table>
<thead>
<tr>
<th>Category 2</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appointment</td>
<td>Patients who are HBsAg positive without presence of Red flags</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category 3</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appointment</td>
<td>No category 3 criteria</td>
</tr>
</tbody>
</table>
PLEASE DO AN ULTRASOUND WITH HEPATITIS B REFERRALS

Because of the risk of hepatocellular carcinoma
Acute Hepatitis B

- The usual course of infection in immunocompetent adults exposed to the virus for the first time
- Many develop clinical hepatitis and virtually all have high ALT

- 95% resolve the infection within 6 months
  - HepBsAg neg
  - HepBsAb pos
  - HepbcAb pos
  - HepBeAg neg
  - HepBeAb pos

- May re-activate if exposed to profound immunosuppression such as chemotherapy
Immunised against Hep B

- HepBsAg neg
- HepBsAb pos
- HepBcAb neg
- HepBeAg neg
- HepBeAb neg

- Most Australians under the age of 30
QUESTIONS?